Web Stats Provided By Google Analytics

The Raw Stem Cell News Feed

The Stem Cell Research Newswire: Comprehensive Real-Time News Feed for Stem Cell Research

Friday, February 20, 2015

REVLIMIDA (Lenalidomide) Approved by the European Commission for the ...

Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation , today announced that the European Commission has approved REVLIMID for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The REVLIMID Marketing Authorisation has been updated to include this new indication in multiple myeloma, building upon the already approved indication of REVLIMID in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

http://ift.tt/1CRDRUW

No comments:

Post a Comment

Popular Stem Cell Roundup Posts